High SEPT9-i1 protein expression is associated with high-grade prostate cancers

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Gilad, Roni ^a   Meir, Karen ^b   Stein, Ilan ^b   German, Larissa ^a   Pikarsky, Eli ^b   Mabjeesh, Nicola J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEPTIN; SEPTIN 9 ISOFORM 1; UNCLASSIFIED DRUG; ISOENZYME; SEPT9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; CANCER CELL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; ADENOCARCINOMA; BONE TUMOR; CANCER GRADING; DISEASE COURSE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEPTINS;

EID: 84929500744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124251     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008; 127:2893-917. doi: 10.1002/ijc.25516 PMID: 21351269
2. Lindstrom S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, et al. Common genetic variants in prostate cancer risk prediction - results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2012; 21:437-44. doi: 10.1158/1055-9965.EPI-11-1038 PMID: 22237985
3. Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res. 2008; 14:5284-91. doi: 10.1158/1078-0432.CCR-07-5162 PMID: 18698048
4. Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL, et al. A viral vaccine encoding pros-tate- specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res. 2010; 16:4046-56. doi: 10.1158/1078-0432.CCR-10-0948 PMID: 20562209
5. Culig Z. New insights into the role of interleukin-6 in human prostate cancer. The Journal of urology. 2009; 182:1255-6. doi: 10.1016/j.juro.2009.07.073 PMID: 19683299
6. Hartwell LH. Genetic control of the cell division cycle in yeast. IV. Genes controlling bud emergence and cytokinesis. Exp Cell Res. 1971; 69:265-76. PMID: 4950437
7. Kinoshita M. The septins. Genome Biol. 2003; 4:236. PMID: 14611653
8. Mostowy S, Bi E, Fuchtbauer EM, Goryachev AB, Montagna C, Nagata K, et al. Highlight: the 5th International Workshop on Septin Biology. Biol Chem. 2014; 395:119-21. doi: 10.1515/hsz-2013-0291 PMID: 24334412
9. Sandrock K, Bartsch I, Blaser S, Busse A, Busse E, Zieger B. Characterization of human septin interactions. Biol Chem. 2011; 392:751-61. doi: 10.1515/BC.2011.081 PMID: 21767235
10. Oh Y, Bi E. Septin structure and function in yeast and beyond. Trends Cell Biol. 2011; 21:141-8. doi: 10.1016/j.tcb.2010.11.006 PMID: 21177106
11. Connolly D, Abdesselam I, Verdier-Pinard P, Montagna C. Septin roles in tumorigenesis. Biol Chem. 2011; 392:725-38. doi: 10.1515/BC.2011.073 PMID: 21740328
12. Amir S, Mabjeesh NJ. SEPT9-V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents. Cancer Biol Ther. 2007; 6:1926-31. PMID: 18075300
13. Chacko AD, McDade SS, Chanduloy S, Church SW, Kennedy R, Price J, et al. Expression of the SEPT9-i4 isoform confers resistance to microtubule-interacting drugs. Cell Oncol (Dordr). 2012; 35:85-93. doi: 10.1007/s13402-011-0066-0 PMID: 22278362
14. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013; 123:3664-71. doi: 10.1172/JCI67230 PMID: 23999440
15. Amir S, Wang R, Matzkin H, Simons JW, Mabjeesh NJ. MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res. 2006; 66:856-66. PMID: 16424018
16. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009; 24:97-106. doi: 10.1152/physiol.00045.2008 PMID: 19364912
17. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol. 2007; 22:559-72. PMID: 17330811
18. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol. 2004; 30:465-8. PMID: 15135470
19. Yutkin V, Pode D, Pikarsky E, Mandelboim O. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. The Journal of urology. 2007; 178:2660-4. PMID: 17945285
20. Santos J, Cerveira N, Bizarro S, Ribeiro FR, Correia C, Torres L, et al. Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. Leukemia research. 2010; 34:615-21. doi: 10.1016/j.leukres.2009.08.018 PMID: 19748670
21. Epstein JI. An update of the Gleason grading system. The Journal of urology. 2010; 183:433-40. doi: 10.1016/j.juro.2009.10.046 PMID: 20006878
22. Stanbery L, D'Silva NJ, Lee JS, Bradford CR, Carey TE, Prince ME, et al. High SEPT9-v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma. Transl Oncol. 2010; 3:239-45. PMID: 20689765
23. Amir S, Golan M, Mabjeesh NJ. Targeted knockdown of SEPT9-v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res. 2010; 8:643-52. doi: 10.1158/1541-7786.MCR-09-0497 PMID: 20407014
24. Chacko AD, Hyland PL, McDade SS, Hamilton PW, Russell SH, Hall PA. SEPT9-v4 expression induces morphological change, increased motility and disturbed polarity. J Pathol. 2005; 206:458-65. PMID: 15902694
25. Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9-v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res. 2007; 67:8554-64. PMID: 17875694
26. Mullins JK, Bonekamp D, Landis P, Begum H, Partin AW, Epstein JI, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. Bju International. 2013; 111:1037-45. doi: 10.1111/j.1464-410X.2012.11641.x PMID: 23464904
27. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. European urology. 2014; 65:1023-31. doi: 10.1016/j.eururo.2014.01.027 PMID: 24491309
28. Welty CJ, Carroll PR. The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer. European urology. 2014; 65:1032-3. doi: 10.1016/j.eururo.2014.02.044 PMID: 24636678